azelaprag + tirzepatide

**azelaprag + tirzepatide** is an investigational combination therapy for weight management and obesity in older adults. Azelaprag is an oral small molecule acting as an *apelin receptor agonist*, while tirzepatide is a once-weekly injectable *dual agonist* for the *glucose-dependent insulinotropic polypeptide (GIP) receptor* and the *glucagon-like peptide-1 (GLP-1) receptor*. The combination is intended to amplify weight loss effects compared to tirzepatide alone.[1][3][5][7][9] Clinical data showed glycemic benefits when azelaprag was used with tirzepatide in preclinical diabetic models.[9] Azelaprag’s mechanism involves activation of apelin receptor, modulating insulin sensitivity and metabolism; tirzepatide activates GIP and GLP-1 pathways to enhance insulin secretion, decrease glucagon, regulate appetite, and promote weight reduction.[2][4][6][8][10]

Other names

BGE-105 (azelaprag)azelaprag + tirzepatide